The race to industrialize artificial intelligence in drug discovery just gained a new signal from the Research Triangle.
Ten63 Therapeutics announced today that it has secured new strategic investment from the Chugai Venture Fund and the Gates Foundation, bringing the Research Triangle Park-based company’s total funding to more than $45 million. The financing is designed to accelerate the expansion of BEYOND, Ten63’s Large Quantum Chemistry Model (LQCM) and AI-driven drug discovery platform.
For a region that has steadily built strength in computational biology, data science, and biopharma, the round is more than a capital event. It positions North Carolina squarely within the next frontier of techbio — where AI is not simply optimizing existing pipelines, but redefining what is scientifically tractable.
From “Undruggable” to Computationally Reachable
Ten63’s BEYOND platform is built to simulate trillions of potential drug candidates per protein target with near experimental accuracy, according to the company, at speeds that exceed traditional computational chemistry approaches by orders of magnitude.
The ambition is bold: to unlock the 80% of proteins historically considered “undruggable,” create differentiated small-molecule therapeutics against high-impact targets, and develop affordable medicines for global health challenges — including human papillomavirus (HPV), with support from the Gates Foundation.
The company framed the financing not simply as an acceleration of timelines, but as an expansion of what is scientifically possible. By building a simulation environment that enables AI systems to explore molecular space at unprecedented scale and precision, Ten63 is pushing toward what it describes as a form of “superintelligence” in drug discovery.
While the language may be forward-leaning, the underlying trend is unmistakable. Across the biopharma sector, AI is evolving from a decision-support tool into a hypothesis-generation engine. The companies that win will not merely apply machine learning to existing workflows — they will reshape the physics layer of discovery itself.
Strategic Capital with Global and Local Signal
The participation of Chugai Venture Fund, the corporate venture arm of Japan-based Chugai Pharmaceutical, adds strategic pharmaceutical validation. Chugai has long been regarded as a science-driven organization with deep biologics and oncology expertise, and its venture investments often signal long-term scientific alignment.
The Gates Foundation’s involvement adds a different dimension — one anchored in global access and affordability. By backing Ten63’s efforts to develop small molecules targeting HPV and other high-burden diseases, the foundation is reinforcing a growing narrative: advanced AI platforms are not solely tools for blockbuster oncology assets, but potential engines for global health equity.
Importantly for the Research Triangle Park ecosystem, this round builds on Ten63’s earlier backing from investors with North Carolina ties. The company has previously attracted support from regional venture participants and ecosystem-aligned capital, reflecting the Triangle’s growing bench of techbio-savvy investors and translational science advocates. As RTP continues to mature beyond its legacy pharma anchors into a startup-driven innovation economy, these capital stacks matter.
They demonstrate that local infrastructure — from university research talent to venture networks — can support computational-first biotech models that historically clustered in Boston or the Bay Area.
AI, Quantum Chemistry, and the RTP Advantage
Ten63’s focus on quantum chemistry modeling underscores a subtle but important shift in AI drug discovery. Many early AI-biotech hybrids concentrated on pattern recognition in biological datasets. Quantum chemistry-based models, by contrast, aim to simulate molecular interactions at a physics-grounded level.
That computational depth aligns well with the Triangle’s interdisciplinary strengths. Anchored by Duke University, the University of North Carolina at Chapel Hill, and North Carolina State University, the region has long blended computational science, engineering, and life sciences. RTP’s proximity to major pharmaceutical operations further strengthens translational pathways.
In an industry increasingly defined by convergence — AI, chemistry, biology, and high-performance computing — regional ecosystems that can cross-train talent across domains hold a structural advantage.
Why This Matters Now
The broader biotech capital markets have remained selective, particularly for early-stage platform companies. Strategic financings — especially those backed by global pharma venture arms and mission-driven foundations — signal confidence in both scientific differentiation and commercial potential.
For Ten63, surpassing $45 million in total funding provides runway to scale its BEYOND platform and advance internal programs. For RTP, it reinforces a narrative that the region is not merely participating in the AI-biotech revolution, but helping to architect it.
If the first wave of AI drug discovery was about proof-of-concept partnerships and data-driven target validation, the next wave will be judged by molecules entering the clinic — and by whether AI can systematically address the vast swaths of biology long written off as inaccessible.
Ten63’s financing does not yet answer that question. But it does mark a meaningful step toward a future where trillions of molecular possibilities are no longer theoretical abstractions — but computable, searchable terrain.
And for North Carolina’s innovation economy, that shift carries implications far beyond a single funding round.
